Study of CD38 and CD56 in Chronic Myeloid Leukemia

Aberrant Expression of CD56 on CD38 Positive Neutrophils as a Novel Diagnostic Tool in Chronic Myeloid Leukemia

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07740603

Enrollment

200

Registered

2026-07-31

Start date

2026-09-01

Completion date

2027-07-01

Last updated

2026-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Myeloid Leukemia (CML)

Brief summary

Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow. The aim of the study is to study expression of CD38 and CD56 in patients with Chronic myeloid leukemia.

Interventions

DIAGNOSTIC_TESTcd 38 and cd 56

prescence of high percentage of cd38 and cd 56

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* patients with chronic myeloid leukemia

Exclusion criteria

* other hematological diseases

Design outcomes

Primary

Measure	Time frame
an increased change in cd 38 and cd 56 in chronic leukemic patients	6 months

Contacts

CONTACTMenna Mostafa Zaki

mennazaki133@gmail.com01152386116

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 6, 2026